Join 37 other subscribers
Tag Archives: Pfizer
Generic drug maker Mylan pulls a mini-Pfizer tax inversion
Taking a page from Pfizer’s playbook, Mylan is buying Abbott Laboratories’ branded specialty and generics businesses in developed markets outside the U.S.. The $5B deal is structured to result in a tax inversion, with the newly formed merged company to be headquartered in the Netherlands. “We see … Continue reading
Posted in Pharmaceutical Industry Tagged Abbott Laboratories, Mylan, Pfizer, tax inversion 1 Comment
Pfizer gives up the chase.
Pfizer is saying today that it does not intend to extend a firm offer for AstraZeneca, bringing an end to its attempt to acquire the UK drug maker. AZ shareholders were split on the latest offer, and a stumble by AZ would … Continue reading
Posted in Pharmaceutical Industry Tagged AstraZeneca, merger, Pfizer Leave a comment
Pfizer raises its bid for AstraZeneca – one last time?
Over the weekend, Pfizer finally made an official offer for AstraZeneca, by raising its bid to $119B (15% higher than the last, unofficial, offer), and increasing the cash portion of the deal from 33% to 45%. AZ had a market cap of … Continue reading
Posted in Pharmaceutical Industry Tagged acquisition, AstraZeneca, megamerger, Pfizer Leave a comment
Pfizer is a shark that can’t stop feeding
So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading
Posted in Pharmaceutical Industry Tagged AstraZeneca, Consolidation, merger, Pfizer, Pharmaceutical industry Leave a comment
Pfizer won’t take no for an answer
Amidst several indications that Pfizer will launch a hostile bid for AstraZeneca if necessary, this quote stands out: Asked whether hostile moves could hurt integration of the two companies, Chief Executive Ian Read said, “No, in my opinion, all it … Continue reading
Posted in Pharmaceutical Industry Tagged AstraZeneca, hostile takeover, Ian Read, merger, Pfizer Leave a comment
Pfizer’s real strategy is (mostly) tax-minimization
Many observers were initially left scratching their heads over Pfizer’s pursuit of AstraZeneca, a company that has had major pipeline troubles of its own. As more information has come out, Pfizer’s strategy is beginning to make sense. They aren’t pursuing an old-style mega … Continue reading
Posted in Pharmaceutical Industry Tagged AstraZeneca, merger, Pfizer, Pharma, tax-avoidance 1 Comment
Undeterred, Pfizer continues its mega merger strategy
Pfizer continues to stalk AstraZeneca, even as other firms abandon mega mergers.
Posted in Pharmaceutical Industry Tagged AstraZeneca, mergers, Pfizer Leave a comment
Pharma megamergers — against the spirit of the times?
Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday. As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading
Posted in Fixing Big Pharma Research, Pharmaceutical Industry Tagged Eli Lilly, GSK, M&A, megamergers, Novartis, Pfizer, Pharmaceutical industry 1 Comment